✦ LIBER ✦

PAR9 IMPACT OF PATIENT'S OUT-OF-POCKET COST ON ADHERENCE AND PERSISTENCE WITH BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS

✍ Scribed by M Gleeson; S Curkendall; V Patel; R Smith; M Zagari

Book ID: 118608464
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 86 KB
Volume: 10
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)68901-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Compliance with biologic therapies for r

Compliance with biologic therapies for rheumatoid arthritis: Do patient out-of-pocket payments matter?

✍ Curkendall, S. ;Patel, V. ;Gleeson, M. ;Campbell, R. S. ;Zagari, M. ;Dubois, R. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

## Abstract ## Objective To assess the impact of patient out‐of‐pocket (OOP) expenditures on adherence and persistence with biologics in patients with rheumatoid arthritis (RA). ## Methods An inception cohort of RA patients with pharmacy claims for etanercept or adalimumab during 2002–2004 was s

PRS22 EFFECT OF PATIENTS' OUT-OF-POCKET

PRS22 EFFECT OF PATIENTS' OUT-OF-POCKET COST ON ADHERENCE AND PERSISTENCE WITH OMALIZUMAB (XOLAIR) THERAPY FOR ALLERGIC ASTHMA

✍ HT Yu; P Solari; AE Wallace; C Sarawate; J Hille; S Curkendall 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

PAR9 A COST MINIMISATION ANALYSE FOR STU

PAR9 A COST MINIMISATION ANALYSE FOR STUDYING THE EFFICIENCY OF BIOLOGIC THERAPIES (BT) IN RHEUMATOID ARTHRITIS (RA). OVERVIEW FOR THE SPANISH SETTING

✍ X Badia; D Serrano; S Magaz 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Impact of medicare part D on access to a

Impact of medicare part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis

✍ Polinski, Jennifer M. ;Mohr, Penny E. ;Johnson, Lorraine 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 334 KB 👁 1 views

Current and emerging therapies for rheum

Current and emerging therapies for rheumatoid arthritis, with a focus on infliximab: clinical impact on joint damage and cost of care in Canada

✍ Anthony Russell; Boulos Haraoui; Edward Keystone; Alice Klinkhoff 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 761 KB

PMS33 COST EFFECTIVENESS OF ABATACEPT IN

PMS33 COST EFFECTIVENESS OF ABATACEPT IN COMPARISON WITH OTHER BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS PATIENTS WHO HAVE FAILED TO METHOTREXATE BASED TREATMENT AT ESSALUD IN 2010

✍ F. Becerra Rojas; C. Benites Chacaltana; E.C. Aiello; C. Zingoni; G. Bergman; P. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB